Published in Nat Med on July 01, 2000
Coenzyme Q10 in Huntington's Disease (HD) (2CARE) | NCT00608881
Role of Minocycline in First Episode Psychosis | NCT00916461
Nitric oxide and peroxynitrite in health and disease. Physiol Rev (2007) 15.49
Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol (2009) 5.65
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A (2003) 4.44
Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res (2007) 3.67
Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci (2007) 3.02
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry (2005) 2.54
Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A (2006) 2.07
Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A (2003) 2.05
HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol (2010) 1.87
A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci U S A (2003) 1.84
Nitric oxide-GAPDH-Siah: a novel cell death cascade. Cell Mol Neurobiol (2006) 1.75
Huntington's disease: can mice lead the way to treatment? Neuron (2011) 1.71
Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke (2010) 1.69
Aging in individuals with the FMR1 mutation. Am J Ment Retard (2004) 1.68
Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A (2004) 1.63
Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins. Nat Chem Biol (2010) 1.62
Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev (2002) 1.61
Minocycline: far beyond an antibiotic. Br J Pharmacol (2013) 1.59
Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol (2010) 1.56
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience (2013) 1.55
Regulation of inducible nitric oxide synthase gene in glial cells. Antioxid Redox Signal (2006) 1.50
Neuroimmune interactions and pain: focus on glial-modulating targets. Curr Opin Investig Drugs (2008) 1.50
Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A (2002) 1.39
Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener (2006) 1.35
Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol Cell Biol (2008) 1.35
The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx (2005) 1.33
Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. BMC Neurosci (2009) 1.33
Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A (2002) 1.29
Prospects for minocycline neuroprotection. Arch Neurol (2010) 1.27
Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ (2012) 1.27
Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J Clin Invest (2007) 1.25
Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci U S A (2002) 1.24
Minocycline prevents osmotic demyelination syndrome by inhibiting the activation of microglia. J Am Soc Nephrol (2010) 1.20
Acute minocycline treatment mitigates the symptoms of mild blast-induced traumatic brain injury. Front Neurol (2012) 1.20
The mitochondrial permeability transition in neurologic disease. Neurochem Int (2007) 1.19
Multiple sclerosis: looking beyond autoimmunity. J R Soc Med (2005) 1.19
Minocycline protects against neurologic complications of rapid correction of hyponatremia. J Am Soc Nephrol (2010) 1.18
Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. J Neurosci (2008) 1.17
Huntingtin inhibits caspase-3 activation. EMBO J (2006) 1.17
Neuroinflammation in Huntington's disease. J Neural Transm (Vienna) (2010) 1.16
Neurobiology of injury to the developing brain. Nat Rev Neurol (2010) 1.16
Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res (2010) 1.15
Huntingtin in health and disease. J Clin Invest (2003) 1.14
Minocycline development for acute ischemic stroke. Transl Stroke Res (2011) 1.12
Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy. Brain Res (2009) 1.12
Novel modulators of poly(ADP-ribose) polymerase. Trends Pharmacol Sci (2006) 1.12
Drosophila models of neurodegenerative disease. NeuroRx (2005) 1.12
Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology (Berl) (2007) 1.12
The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther (2009) 1.10
Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One (2011) 1.10
A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model. Brain Res (2008) 1.08
Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-beta variants in cells composing the cerebral vessel walls. FASEB J (2009) 1.08
Autophagy, inflammation and neurodegenerative disease. Eur J Neurosci (2010) 1.08
Minocycline prevents retinal inflammation and vascular permeability following ischemia-reperfusion injury. J Neuroinflammation (2013) 1.08
Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology (2011) 1.07
The immune response of stem cells in subretinal transplantation. Stem Cell Res Ther (2015) 1.05
Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess. Am J Pathol (2007) 1.05
Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx (2004) 1.05
Anti-inflammatory impact of minocycline in a mouse model of tauopathy. Front Psychiatry (2010) 1.03
Caspase-3 contributes to ZO-1 and Cl-5 tight-junction disruption in rapid anoxic neurovascular unit damage. PLoS One (2011) 1.03
Bacterial and human peptidylarginine deiminases: targets for inhibiting the autoimmune response in rheumatoid arthritis? Arthritis Res Ther (2010) 1.03
Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases. Exp Neurol (2012) 1.02
Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents: Differences in response based on strains and solvents. Brain Res (2006) 1.02
Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models. Chem Biol (2010) 1.02
High-throughput screening identifies two classes of antibiotics as radioprotectors: tetracyclines and fluoroquinolones. Clin Cancer Res (2009) 1.02
The inflammation hypothesis in geriatric depression. Int J Geriatr Psychiatry (2011) 1.01
Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition. Mol Psychiatry (2016) 1.01
Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model. Genetics (2011) 1.00
Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis (2010) 1.00
Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body. Histol Histopathol (2008) 0.99
Brain tissue responses to neural implants impact signal sensitivity and intervention strategies. ACS Chem Neurosci (2015) 0.99
Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J Biol Chem (2010) 0.99
Neuroprotection in the newborn infant. Clin Perinatol (2009) 0.99
Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions. Glia (2011) 0.99
A new mouse mutant of the Cdh23 gene with early-onset hearing loss facilitates evaluation of otoprotection drugs. Pharmacogenomics J (2010) 0.98
Role of oral Minocycline in acute encephalitis syndrome in India - a randomized controlled trial. BMC Infect Dis (2016) 0.98
Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival. Neurotoxicology (2009) 0.98
Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A (2006) 0.96
The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J Neurosci (2011) 0.96
Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. NeuroRx (2004) 0.96
The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi. J Infect Dis (2009) 0.95
Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis Model Mech (2011) 0.94
Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion (2009) 0.94
Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range. Cell Mol Neurobiol (2007) 0.93
Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease. J Neurosci Res (2009) 0.92
Inhibition of trypsin-like cysteine proteinases (gingipains) from Porphyromonas gingivalis by tetracycline and its analogues. Antimicrob Agents Chemother (2001) 0.92
Role for Toll-like receptor 2 in the immune response to Streptococcus pneumoniae infection in mouse otitis media. Infect Immun (2009) 0.92
Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics (2008) 0.92
Effects of caspase-1 knockout on chronic neural recording quality and longevity: insight into cellular and molecular mechanisms of the reactive tissue response. Biomaterials (2014) 0.92
The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. NeuroRx (2004) 0.91
Effects of minocycline on Fas-mediated fulminant hepatitis in mice. Br J Pharmacol (2005) 0.91
Hydrogen peroxide-induced Akt phosphorylation regulates Bax activation. Biochimie (2009) 0.90
Mechanisms and potential therapeutic applications of microglial activation after brain injury. CNS Neurosci Ther (2014) 0.89
Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo. Neurobiol Dis (2007) 0.89
Attenuation of oxidative stress, inflammation and apoptosis by minocycline prevents retrovirus-induced neurodegeneration in mice. Brain Res (2009) 0.89
Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. J Neurochem (2010) 0.89
Minocycline and sulforaphane inhibited lipopolysaccharide-mediated retinal microglial activation. Mol Vis (2007) 0.88
Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One (2010) 0.88
Doxycycline inhibits proinflammatory cytokines but not acute cerebral cytogenesis after hypoxia-ischemia in neonatal rats. J Psychiatry Neurosci (2010) 0.88
The sequence of the human genome. Science (2001) 101.55
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
A human genome diversity cell line panel. Science (2002) 14.11
Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (1997) 11.53
miR-21-mediated tumor growth. Oncogene (2006) 9.90
Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol (1985) 7.93
FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell (1994) 7.66
Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem (2001) 7.03
Cooperative regulation of cell polarity and growth by Drosophila tumor suppressors. Science (2000) 6.44
Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science (2003) 6.35
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A (2006) 6.33
Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell (1998) 6.24
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med (1996) 5.96
Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J Virol (2000) 5.44
Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology (2002) 5.40
Rapid induction of Alzheimer A beta amyloid formation by zinc. Science (1994) 5.34
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (2001) 5.28
PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol (1998) 5.01
A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest (2001) 4.98
Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res (1997) 4.89
American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) (2012) 4.82
Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet (1996) 4.77
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72
Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology (1999) 4.59
A 1.5 million-base pair inversion polymorphism in families with Williams-Beuren syndrome. Nat Genet (2001) 4.58
Dicistronic targeting constructs: reporters and modifiers of mammalian gene expression. Proc Natl Acad Sci U S A (1994) 4.44
Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill (2013) 4.37
Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature (2000) 4.31
Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci (1999) 4.27
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27
CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol (1997) 4.01
Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science (1999) 3.98
15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A (2000) 3.89
Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet (1997) 3.64
Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med (2000) 3.60
Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol (1995) 3.60
Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron (1998) 3.59
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol (1989) 3.58
A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron (1999) 3.50
Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol (2001) 3.46
Assembly of the mitochondrial membrane system: sequences of yeast mitochondrial valine and an unusual threonine tRNA gene. Cell (1979) 3.39
The histidyl-tRNA synthetase-related sequence in the eIF-2 alpha protein kinase GCN2 interacts with tRNA and is required for activation in response to starvation for different amino acids. Mol Cell Biol (1995) 3.36
Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain. Cell (1998) 3.22
Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science (2000) 3.12
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology (2012) 3.12
Codon recognition rules in yeast mitochondria. Proc Natl Acad Sci U S A (1980) 3.11
Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron (1995) 3.08
Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet (2000) 3.07
High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med (2001) 3.04
Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol (2002) 3.02
DNA markers for nervous system diseases. Science (1984) 3.02
Projections of the medial and lateral prefrontal cortices to the amygdala: a Phaseolus vulgaris leucoagglutinin study in the rat. Neuroscience (1996) 3.01
Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro Surveill (2013) 2.99
Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci U S A (1997) 2.99
Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature (1999) 2.97
Inactivation of the mouse Huntington's disease gene homolog Hdh. Science (1995) 2.96
Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J Neurosci (1997) 2.93
Evidence for in vivo but not in vitro expression of a Borrelia burgdorferi outer surface protein F (OspF) homologue. Mol Microbiol (1995) 2.92
Alcohol drinking and all cancer mortality: a meta-analysis. Ann Oncol (2012) 2.83
Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta -catenin signaling is activated in human colon tumors. Proc Natl Acad Sci U S A (2001) 2.77
Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci U S A (2005) 2.75
Identification of the paromomycin-resistance mutation in the 15 S rRNA gene of yeast mitochondria. J Biol Chem (1982) 2.70
Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene (2007) 2.68
Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet (2000) 2.67
Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. J Biol Chem (2001) 2.62
Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet (2001) 2.55
Ketamine anesthesia during the first week of life can cause long-lasting cognitive deficits in rhesus monkeys. Neurotoxicol Teratol (2011) 2.41
Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat Med (1998) 2.38
Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke (1997) 2.38
The gut as a portal of entry for bacteremia. Role of protein malnutrition. Ann Surg (1987) 2.38
Dynamics of bubble oscillation in constrained media and mechanisms of vessel rupture in SWL. Ultrasound Med Biol (2001) 2.37
Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol (1997) 2.35
Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med (2001) 2.33
Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet (1998) 2.31
Receptors for polytropic and xenotropic mouse leukaemia viruses encoded by a single gene at Rmc1. Nat Genet (1999) 2.28
Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci (1993) 2.27
The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology (2000) 2.20
A clustering approach to multireference alignment of single-particle projections in electron microscopy. J Struct Biol (2010) 2.19
CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet (2000) 2.18
Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol (2001) 2.17
Selective sparing of a class of striatal neurons in Huntington's disease. Science (1985) 2.16
Rho3 of Saccharomyces cerevisiae, which regulates the actin cytoskeleton and exocytosis, is a GTPase which interacts with Myo2 and Exo70. Mol Cell Biol (1999) 2.15
Accessory protein facilitated CFTR-CFTR interaction, a molecular mechanism to potentiate the chloride channel activity. Cell (2000) 2.15
Characterization of human tracheal epithelial cells transformed by an origin-defective simian virus 40. Proc Natl Acad Sci U S A (1988) 2.15
Borrelia burgdorferi supercoiled plasmids encode multicopy tandem open reading frames and a lipoprotein gene family. J Bacteriol (1996) 2.14
Intracellular calcium release mediated by sphingosine derivatives generated in cells. Science (1990) 2.13
Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res (2000) 2.13
A new diamond search algorithm for fast block-matching motion estimation. IEEE Trans Image Process (2000) 2.13
Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell (1997) 2.13
The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology (1993) 2.12
Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci U S A (1993) 2.10
Cytoplasmic dynein function is essential in Drosophila melanogaster. Genetics (1996) 2.10